FDA Advisers Consider Novavax COVID-19 Vaccine This Week
An FDA panel will consider Novavax's COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
WebMD Health News
source https://www.medscape.com/viewarticle/975076?src=rss
WebMD Health News
source https://www.medscape.com/viewarticle/975076?src=rss
Comments
Post a Comment